Follow The Filings

SRTA Strata Critical Medical

Strata Critical Medical earnings company data as of 4:48 AM ET 10/23

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS 0.01 — —
Rev — — —

Insider trades

Open-market buys and sales by SRTA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SRTA insider trades
  • $98K bought by 2 insiders
  • $125K sold by 1 insider outside a trading plan
  • $382K sold by 1 insider under 10b5-1 plans
  1. Reginald Love Director
    Sale
    $29K 5,091 shares at $5.75 3.4% of stake
    Traded Aug 10 Filed Aug 13
  2. Amir Cohen Chief Accounting Officer
    Planned sale
    $299K 50,875 shares at $5.89 25% of stake
    Traded May 21–22 Filed May 26
  3. Amir Cohen Chief Accounting Officer
    Planned sale
    $83K 14,306 shares at $5.79 6.6% of stake
    Traded May 11 Filed May 13
  4. William A. Heyburn CEO
    Buy
    $76K 17,000 shares at $4.47 +1.2% to stake
    Traded Dec 9, 2025 Filed Dec 10, 2025
  5. Andrew Lauck Director
    Buy
    $22K 5,000 shares at $4.37 +3.8% to stake
    Traded Dec 5, 2025 Filed Dec 5, 2025
  6. Reginald Love Director
    Sale
    $48K 11,000 shares at $4.37 8.8% of stake
    Traded Nov 20, 2025 Filed Nov 24, 2025
  7. Reginald Love Director
    Sale
    $47K 11,000 shares at $4.31 8.1% of stake
    Traded Nov 19, 2025 Filed Nov 20, 2025

Also filed in the last 12 months, not counted as buying or selling: 30 share withholdings for taxes, 28 stock grants, 4 sales to cover taxes, and 2 option exercises.

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
SCHEDULE 13D —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
SCHEDULE 13G —
8-K 5.07
SCHEDULE 13D/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.